@article{93ab841fbc5c4b9cb37bd8c9c37ce4f5,
title = "A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer",
abstract = "In a phase Ib clinical trial, Ott et al. demonstrate feasibility, safety, and immunogenicity of the combination of personalized neoantigen vaccines and PD-1 inhibition in patients with advanced solid tumors. Vaccine-induced T cells persist over time, exhibit cytotoxic potential, and can migrate to tumors. Epitope spread and major pathologic tumor responses were detected following vaccination.",
keywords = "NEO-PV-01, T cell, anti-PD-1, cancer vaccine, checkpoint inhibitor, epitope spread, immunotherapy, metastatic cancer, neoantigen, personalized vaccine",
author = "Ott, {Patrick A.} and Siwen Hu-Lieskovan and Bartosz Chmielowski and Ramaswamy Govindan and Aung Naing and Nina Bhardwaj and Kim Margolin and Awad, {Mark M.} and Hellmann, {Matthew D.} and Lin, {Jessica J.} and Terence Friedlander and Bushway, {Meghan E.} and Balogh, {Kristen N.} and Sciuto, {Tracey E.} and Victoria Kohler and Turnbull, {Samantha J.} and Rana Besada and Curran, {Riley R.} and Benjamin Trapp and Julian Scherer and Asaf Poran and Dewi Harjanto and Dominik Barthelme and Ting, {Ying Sonia} and Dong, {Jesse Z.} and Yvonne Ware and Yuting Huang and Zhengping Huang and Amy Wanamaker and Cleary, {Lisa D.} and Moles, {Melissa A.} and Kelledy Manson and Joel Greshock and Khondker, {Zakaria S.} and Ed Fritsch and Rooney, {Michael S.} and Mark DeMario and Gaynor, {Richard B.} and Lakshmi Srinivasan",
note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",
year = "2020",
month = oct,
day = "15",
doi = "10.1016/j.cell.2020.08.053",
language = "English",
volume = "183",
pages = "347--362.e24",
journal = "Cell",
issn = "0092-8674",
number = "2",
}